Patents by Inventor James D. Otvos

James D. Otvos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11988679
    Abstract: Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: May 21, 2024
    Assignee: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova
  • Patent number: 11990243
    Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes using defined mathematical models of short term risk (STR) and longer term risk of progression. The evaluations can stratify risk for patients having the same glucose measurement, particularly those with intermediate or low (normal) fasting plasma glucose (FPG) values. The STR or IR (insulin resistance) model(s) may include an inflammatory biomarker such as an NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. Embodiments of the invention also provide methods, systems and circuits that generate STR scores as a marker of beta-cell dysfunction or impairment.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: May 21, 2024
    Assignee: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova
  • Publication number: 20240125719
    Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosample may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.
    Type: Application
    Filed: September 21, 2023
    Publication date: April 18, 2024
    Applicant: Liposcience, Inc.
    Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
  • Patent number: 11942187
    Abstract: Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and/or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL/RHDL.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: March 26, 2024
    Assignee: LIPOSCIENCE, INC.
    Inventor: James D. Otvos
  • Publication number: 20240096497
    Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.
    Type: Application
    Filed: June 16, 2023
    Publication date: March 21, 2024
    Applicant: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
  • Publication number: 20240044826
    Abstract: Disclosed are methods and systems for evaluating various health markers to distinguish various health risks. In one embodiment, the method comprises evaluating biomarkers to determine a relative risk of premature all-cause mortality in metabolic malnutrition-inflammation syndrome (MMIS). A method may include obtaining NMR-derived measurements of GlycA, S-HDLP, branched chain amino acids (BCAAs), and citrate from a subject's sample.
    Type: Application
    Filed: August 7, 2023
    Publication date: February 8, 2024
    Inventor: James D. Otvos
  • Patent number: 11782002
    Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: October 10, 2023
    Assignee: LipoScience, Inc.
    Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
  • Patent number: 11710568
    Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: July 25, 2023
    Assignee: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
  • Patent number: 11703501
    Abstract: Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: July 18, 2023
    Assignee: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova
  • Patent number: 11692995
    Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: July 4, 2023
    Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
  • Publication number: 20230024795
    Abstract: Described herein are methods and systems for the determination of constituents in biosamples by NMR spectroscopy and more specifically for the determination of lipoprotein constituents LP-X, LP-Y, and LP-Z in blood plasma and serum.
    Type: Application
    Filed: September 19, 2022
    Publication date: January 26, 2023
    Inventors: James D. Otvos, Irina Shalaurova, Alan Remaley, Maureen Sampson, Lita Freeman
  • Patent number: 11467171
    Abstract: Described herein are methods and systems for the determination of constituents in biosamples by NMR spectroscopy and more specifically for the determination of lipoprotein constituents LP-X, LP-Y, and LP-Z in blood plasma and serum.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: October 11, 2022
    Inventors: James D. Otvos, Irina Shalaurova, Alan Remaley, Maureen Sampson, Lita Freeman
  • Publication number: 20220137076
    Abstract: Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
    Type: Application
    Filed: January 4, 2022
    Publication date: May 5, 2022
    Applicant: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova
  • Publication number: 20220043013
    Abstract: Disclosed are methods and systems to determine a subject's metabolic vulnerability index (MVX) score using at least one defined mathematical model of risk. The methods comprise evaluating various biomarkers to distinguish various health risks. In one embodiment, the method comprises evaluating biomarkers to determine a relative risk of premature all-cause mortality. The model may include NMR-derived measurements of GlycA, S-HDLP, branched chain amino acids (BCAAs), ketone bodies, total serum protein, and citrate in at least one biosample of the subject.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Applicant: LipoScience, Inc.
    Inventors: James D. Otvos, Irine Y. Shalaurova
  • Publication number: 20220043086
    Abstract: The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Applicant: LipoScience, Inc.
    Inventors: James D. Otvos, Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman, Donald R. Deuel
  • Patent number: 11231429
    Abstract: Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: January 25, 2022
    Assignee: Liposcience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova
  • Publication number: 20220011388
    Abstract: Described herein are methods for the determination of patient mortality from alcoholic hepatitis in biosamples by NMR spectroscopy and more specifically for the determination of a Z index score based on lipoprotein constituent LP-Z in blood plasma and serum.
    Type: Application
    Filed: November 7, 2019
    Publication date: January 13, 2022
    Inventors: Zhenghui Gordon Jiang, James D. Otvos, Irina Shalaurova, Elias J. Jeyarajah, Margery A. Connelly, Michael Curry, Nezam Afdhal, Yury Popov, Maria Perez-Matos
  • Patent number: 11156621
    Abstract: Disclosed are methods and systems to determine a subject's metabolic vulnerability index (MVX) score using at least one defined mathematical model of risk. The methods comprise evaluating various biomarkers to distinguish various health risks. In one embodiment, the method comprises evaluating biomarkers to determine a relative risk of premature all-cause mortality. The model may include NMR-derived measurements of GlycA, S-HDLP, branched chain amino acids (BCAAs), ketone bodies, total serum protein, and citrate in at least one biosample of the subject.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 26, 2021
    Assignee: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova
  • Patent number: 11156685
    Abstract: The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 26, 2021
    Assignee: Liposcience, Inc.
    Inventors: James D. Otvos, Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman, Donald R. Deuel
  • Publication number: 20210304898
    Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes using defined mathematical models of short term risk (STR) and longer term risk of progression. The evaluations can stratify risk for patients having the same glucose measurement, particularly those with intermediate or low (normal) fasting plasma glucose (FPG) values. The STR or IR (insulin resistance) model(s) may include an inflammatory biomarker such as an NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. Embodiments of the invention also provide methods, systems and circuits that generate STR scores as a marker of beta-cell dysfunction or impairment.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 30, 2021
    Applicant: LipoScience, Inc.
    Inventors: James D. Otvos, Irina Y. Shalaurova